Horse Chestnut: Chronic Venous Insufficiency Evidence

If horse chestnut has a claim to a place in mainstream medicine, it is here. Chronic venous insufficiency is the one condition for which a standardised horse chestnut seed extract has been tested in a series of randomised, placebo-controlled trials, summarised in a Cochrane review that was published in 2002 and updated repeatedly until 2012, and accepted by the European Medicines Agency as a "well-established use".

This page reads that evidence closely: what the condition is, what was measured, how large the effects were, how the headline number changed as more trials were added, what the famous compression-stocking trial actually showed, and where the evidence stops. Throughout, "the extract" means a standardised seed extract (usually abbreviated HCSE), not raw seeds, bark or leaves — those are poisonous and were never what the trials tested.

Table of Contents

  1. What Chronic Venous Insufficiency Is
  2. What the Trials Measured
  3. The Cochrane Review, Version by Version
  4. Why the Pooled Number Shrank
  5. The Siebert Meta-Analysis
  6. The Compression-Stocking Trial
  7. Venous Leg Ulcers
  8. Post-Thrombotic Syndrome
  9. How It Compares With Other Venoactive Drugs
  10. Doses and Durations Used in Trials
  11. Where the Evidence Stops
  12. Key Research Papers
  13. Connections

What Chronic Venous Insufficiency Is

Blood returns from the legs to the heart uphill. The calf muscles squeeze the deep veins with every step, and small one-way valves inside the veins stop the blood falling back between squeezes. When those valves stretch or fail, blood pools in the lower legs and pressure in the veins stays high. Over months and years that produces the familiar picture of chronic venous insufficiency (CVI): ankle swelling that worsens through the day, legs that feel heavy and tired, aching, itching, night-time calf cramps, visible varicose veins, and in more advanced cases brown skin discoloration, hardened skin and ulcers near the ankle.

It is very common. A 2024 review of herbal drugs for chronic venous disease puts its prevalence at 20–80% of the population worldwide, a wide range that reflects how differently studies define the condition, from a few spider veins to open ulcers. The EMA's monograph wording for horse chestnut describes the target condition as "characterised by swollen legs, varicose veins, a feeling of heaviness, pain, tiredness, itching, tension and cramps in the calves".

Standard care is built around compression — stockings or bandages that squeeze the leg from outside — plus leg elevation, walking, and procedures to close or remove faulty veins. The Cochrane review's own background section explains why an oral option attracts interest: compression often causes discomfort and is associated with poor compliance.

The animation How Veins Return Blood shows the calf-muscle pump and a failing valve.

Back to Table of Contents

What the Trials Measured

Horse chestnut trials used a mix of objective measurements and symptom scores:

The EMA report notes that most trials classified patients using the Widmer scale and that 82% of participants in trials that used it were in stages I–II, meaning swelling and skin changes but mostly without ulcers. The trials therefore tell us about moderate disease, not about healing ulcers.

Back to Table of Contents

The Cochrane Review, Version by Version

Max Pittler and Edzard Ernst, then at the University of Exeter, published a criteria-based systematic review in 1998 and then a Cochrane review in 2002, updated in 2004, 2006, 2008, 2010 and 2012. Every version included only randomised trials of oral horse chestnut seed extract used on its own, against placebo or another treatment. Combination products were excluded.

1998 (Archives of Dermatology). All placebo-controlled studies suggested the extract was superior to placebo, with reduced lower-leg volume, reduced calf and ankle circumference, and reduced leg pain, itching, fatigue and tenseness. Five comparison trials suggested the extract and O-(β-hydroxyethyl)-rutosides were equally effective, and one suggested equivalence with compression. The authors called it "a treatment option for CVI that is worth considering."

2002. Six placebo-controlled trials assessed leg pain and all reported a significant reduction. A meta-analysis of four trials (239 people) found a leg-volume reduction of 58.6 ml compared with placebo (95% CI 24.9 to 92.2).

2004. A meta-analysis of five trials (289 people) found a reduction of 56.3 ml (95% CI 24.1 to 88.5).

2006 and 2012. With a sixth trial added, the pooled analysis (502 people) found a reduction of 32.1 ml (95% CI 13.49 to 50.72). Seven placebo-controlled trials assessed leg pain; six reported a significant reduction and one reported improvement from baseline. In one trial with usable pain data, the difference was 42.4 mm on a 100 mm scale.

Every version reached the same conclusion: the extract appears efficacious and safe as a short-term treatment, "several caveats exist", and larger definitive trials are needed.

Back to Table of Contents

Why the Pooled Number Shrank

The leg-volume estimate fell from 58.6 ml (2002) to 56.3 ml (2004) and then to 32.1 ml once the pooled analysis reached six trials and 502 people. The conclusion did not change — the confidence interval still excludes zero — but the size of the effect roughly halved.

That pattern is common in medicine. Early, small trials often report larger effects than later, bigger ones, partly by chance and partly because small positive studies are more likely to be published and found first. The confidence interval of the latest estimate runs from about 13 ml to about 51 ml, so the true average effect could be modest. For scale, the compression trial described below found swelling falling by about 44 to 47 ml with active treatment.

A few millilitres of leg volume is not something a patient sees directly. What matters to people is whether the leg feels lighter, aches less and swells less by evening; the pain data point the same way as the volume data, but fewer trials reported pain in a form that could be pooled.

Back to Table of Contents

The Siebert Meta-Analysis

A separate 2002 meta-analysis by Siebert and colleagues in Munich took a different approach: it combined 13 randomised trials (1,051 patients) with three large observational studies (10,725 patients) that followed people taking the extract in routine practice.

The observational studies showed improvement in pain, swelling and leg heaviness in everyday use, but observational studies have no comparison group, so improvement could also reflect time, other treatments or expectation. The authors called for further randomised trials and careful long-term observational studies.

Back to Table of Contents

The Compression-Stocking Trial

Diehm and colleagues' 1996 trial in The Lancet is the study behind the frequently repeated statement that horse chestnut works "as well as compression stockings". It enrolled 240 patients with CVI and randomised them, for 12 weeks, to class II compression stockings, the extract (50 mg aescin twice daily) or placebo, in a partially blinded design.

Results for the intention-to-treat group, in the more severely affected leg:

Both active treatments reduced swelling significantly compared with placebo, and the two were statistically equivalent. The authors interpreted compression and the extract as alternative therapies for swelling from CVI. Their own abstract also records a limitation that is often left out: "in this design, however, compression could not be proven as standard with regard to oedema reduction in the statistical test procedure." The trial drew published letters in the same journal, including one by Vayssairat and colleagues.

The trial measured swelling over three months. It did not test which approach better prevents ulcers, skin damage or progression over years, and it does not show that the two are interchangeable for every person with venous disease.

Back to Table of Contents

Venous Leg Ulcers

Ulcers are the most serious stage of CVI, and the evidence for horse chestnut there is much thinner. The only ulcer study in the records reviewed for this page is an economic analysis by Leach and colleagues, built on a 12-week randomised, placebo-controlled trial in South Australia (2002–2004) involving 54 people with venous ulcers treated by a district nursing service. Adding the extract to dressings and compression was calculated to be more cost-effective than conventional therapy alone, with average savings of AUD 95 in organisational costs and AUD 10 in dressing materials per patient, largely because dressings were changed less often. The abstract does not report healing rates, and the authors called for further study.

A 2025 review of venoactive compounds, using a formal evidence-grading system, gave its highest grade for ulcer healing to other agents — micronised purified flavonoid fraction, sulodexide and pentoxifylline — not to horse chestnut.

Back to Table of Contents

Post-Thrombotic Syndrome

Post-thrombotic syndrome is chronic leg pain, swelling, heaviness and skin change that follows a deep-vein thrombosis (DVT). In reviews by Susan Kahn of McGill University, more than one-third of people with DVT develop it, and 5–10% develop severe disease that can lead to ulcers. Those reviews describe compression stockings as the cornerstone of managing the syndrome, and state that venoactive medications such as aescin and rutosides "may provide short-term relief" of symptoms. That is a cautious, short-term statement; no trial of horse chestnut specifically in post-thrombotic syndrome appears in the records reviewed here.

More on the clot itself: Deep Vein Thrombosis.

Back to Table of Contents

How It Compares With Other Venoactive Drugs

Horse chestnut is one of several plant-derived "venoactive" products. A 2025 review of the whole class found that venoactive compounds share similar laboratory and clinical effects — sealing the lining of blood vessels, improving lymphatic drainage, reducing swelling, improving vein tone and reducing white-cell adhesion to vein walls — and that the evidence for effects on symptoms and swelling "has shown some variability". It rated micronised purified flavonoid fraction and a Ruscus (butcher's broom) combination as having the highest-quality evidence.

A 2022 review in American Family Physician rated both Ruscus extract and horse chestnut seed as having moderate-quality evidence for improving swelling from CVI, and described compression as effective for most causes of swelling. The 1998 review found horse chestnut and hydroxyethyl rutosides about equally effective in five comparison trials. The EMA report adds that one trial found horse chestnut inferior to a pine-bark extract for swelling.

Related pages: Hesperidin and diosmin, Rutin, Gotu Kola, and Pine Bark.

Back to Table of Contents

Doses and Durations Used in Trials

According to the EMA assessment report, 14 of the 17 trials in the 2012 Cochrane review used capsules of 240–290 mg dry extract providing 50 mg aescin, taken twice daily (100 mg aescin per day). Two used a larger capsule providing 75 mg aescin twice daily (150 mg per day), and one unpublished trial gave no details. Trials lasted 2 to 16 weeks; three trials using 100 mg aescin daily reported a significant reduction in leg volume after two weeks. The EMA's well-established-use monograph is built on the 100 mg daily figure, and its public summary states that treatment may be needed for at least four weeks before symptoms improve.

These are descriptions of what was tested. There are no long-term trials: nothing in this evidence base runs beyond about four months.

Back to Table of Contents

Where the Evidence Stops

Even so, the direction of the evidence has been consistent for nearly three decades, and it is stronger than the evidence for most herbal products.

Back to Table of Contents

Key Research Papers

  1. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. The Cochrane database of systematic reviews. 2012;11(11):CD003230. PubMed PMID: 23152216
  2. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. The Cochrane database of systematic reviews. 2006;(1):CD003230. PubMed PMID: 16437450
  3. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. The Cochrane database of systematic reviews. 2004;(2):CD003230. PubMed PMID: 15106197
  4. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. The Cochrane database of systematic reviews. 2002;(1):CD003230. PubMed PMID: 11869657
  5. Pittler MH, Ernst E. Horse-chestnut seed extract for chronic venous insufficiency. A criteria-based systematic review. Archives of dermatology. 1998;134(11):1356-60. PubMed PMID: 9828868
  6. Underland V, Sæterdal I, Nilsen ES. Cochrane summary of findings: horse chestnut seed extract for chronic venous insufficiency. Global advances in health and medicine. 2012;1(1):122-3. PubMed PMID: 24278808
  7. Siebert U, Brach M, Sroczynski G, et al.. Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies. International angiology : a journal of the International Union of Angiology. 2002;21(4):305-15. PubMed PMID: 12518108
  8. Diehm C, Trampisch HJ, Lange S, et al.. Comparison of leg compression stocking and oral horse-chestnut seed extract therapy in patients with chronic venous insufficiency. Lancet (London, England). 1996;347(8997):292-4. PubMed PMID: 8569363
  9. Vayssairat M, Debure C, Maurel A, et al.. Horse-chestnut seed extract for chronic venous insufficiency. Lancet (London, England). 1996;347(9009):1182; author reply 1183. PubMed PMID: 8609777
  10. Leach MJ, Pincombe J, Foster G. Using horsechestnut seed extract in the treatment of venous leg ulcers: a cost-benefit analysis. Ostomy/wound management. 2006;52(4):68-70, 72-4, 76-8. PubMed PMID: 16636364
  11. Patel H, Skok C, DeMarco A. Peripheral Edema: Evaluation and Management in Primary Care. American family physician. 2022;106(5):557-564. PubMed PMID: 36379502
  12. Gloviczki ML, Kakkos SK, Urbanek T, et al.. The role of venoactive compounds in the treatment of chronic venous disease. Journal of vascular surgery. Venous and lymphatic disorders. 2025;13(5):102258. PubMed PMID: 40348378
  13. Bencsik T, Balázs VL, Farkas Á, et al.. Herbal drugs in chronic venous disease treatment: An update. Fitoterapia. 2024;179():106256. PubMed PMID: 39419127
  14. Kahn SR. How I treat postthrombotic syndrome. Blood. 2009;114(21):4624-31. PubMed PMID: 19741190
  15. Kahn SR. The post thrombotic syndrome. Thrombosis research. 2011;127 Suppl 3():S89-92. PubMed PMID: 21262451

PubMed Topic Searches

  1. PubMed: horse chestnut seed extract, chronic venous insufficiency, randomised trials
  2. PubMed: venoactive drugs in chronic venous disease
  3. PubMed: horse chestnut and venous leg ulcers

Back to Table of Contents

Connections

Back to top